TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06245980

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: According to whether SGLT2i was used
Study: NCT01829152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHM
Study: NCT00552435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Description: Laser therapy is applied using a slit lamp and specific laser contact lens.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Description: Laser therapy is applied using a slit lamp and specific laser contact lens.
Study: NCT02428725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
Study: NCT04189887

Intervention type: BEHAVIORAL
Intervention: aerobic exercise (cycling)
Description: People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning

Intervention type: BEHAVIORAL
Intervention: aerobic exercise (cycling)
Description: People who perform aerobic exercise will ride on a stationary bike for 20 minutes after motor skill learning

Intervention type: BEHAVIORAL
Intervention: Implicit sequence learning
Description: All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.

Intervention type: BEHAVIORAL
Intervention: Implicit sequence learning
Description: All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.

Intervention type: BEHAVIORAL
Intervention: Implicit sequence learning
Description: All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.

Intervention type: BEHAVIORAL
Intervention: Implicit sequence learning
Description: All participants will practice the serial reaction time task (SRTT) on the first day, and retention performance will be assessed immediately, on the 2nd day, and on the 7th day of study.
Study: NCT02471599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tonsillectomy
Description: The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: non-tonsillectomy
Description: The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
Study: NCT01572285

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transforaminal dexamethasone injection
Description: Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham procedure using a non-penetrating needle
Study: NCT00299429

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting and minimally invasive bypass surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI with DES
Description: PCI with DES
Study: NCT00287378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: omalizumab as per weight and IgE
Study: NCT04059315

Intervention type: OTHER
Intervention: surgical treatment of facial bone fracture
Description: oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.

Intervention type: OTHER
Intervention: surgical treatment of facial bone fracture
Description: oral and maxillofacial injury patients admitted in our hospital. patients are getting treatment of soft and bone frature as follow soft tissue repaire, IMF, ORIF, consrvative.
Study: NCT04316988

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonography
Description: A real time 2D ultrasound evaluation was done over the trachea of the patient.
Study: NCT01614691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1203
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1203
Description: Active

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1203
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02922049

Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies with histopathology
Description: All samples taken by biopsies will be correlated with the images taken by CLE.
Study: NCT05709938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine and regular insulin versus NPH and regular insulin
Description: Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine and regular insulin versus NPH and regular insulin
Description: Patients with type 1 diabetes (T1DM) in group A received insulin glargine as basal therapy at night and regular insulin given prior to each main meal.~Patients in group B were given NPH and regular insulin in split and mix method in the morning and evening.
Study: NCT03346980

Intervention type: DIAGNOSTIC_TEST
Intervention: Esophagogastroduodenoscopy
Description: All patients will be evaluated with both standard HD gastroscope and side-viewing duodenoscope; the latter to ensure proper visualization of the major papilla.
Study: NCT02920242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin (Sandoz GmbH) tablet
Description: 200 mg tablet administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin (Xifaxan)
Description: 200 mg tablet administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tablet administered orally
Study: NCT00577798

Intervention type: PROCEDURE
Intervention: contrast-enhanced magnetic resonance imaging
Description: Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake). Participants will have already received doxorubicin hydrochloride as standard therapy when undergoing chemotherapy for non-Hogdkin's lymphoma and Hogdkin's lymphoma.
Study: NCT03825861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, Irinotecan 180mg/m2, 5-FU 400mg/m2 bolus followed by 2400mg/m2 continuous infusion.
Study: NCT04344561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Positioning
Description: Investigators will adjust the positioning of hospital beds to assess improvements in oxygenation and respiratory status.
Study: NCT02296983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-ZEBOV
Description: VSV-ZEBOV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-ZEBOV
Description: VSV-ZEBOV
Study: NCT03326336

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Gene therapy: GS030-DP AND Medical device: GS030-MD
Description: GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
Study: NCT02380469

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Identification and provision of lacking information
Description: The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Identification and provision of lacking information
Description: The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
Study: NCT04133142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block, inter fascial nerve block
Description: regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block, inter fascial nerve block
Description: regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block, inter fascial nerve block
Description: regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral nerve block, inter fascial nerve block
Description: regional anaesthesia by Inter fascial block, peripheral nerve block. The type of block would be the most appropriate to cover the dermatomes involved in the Herpes according to the mapping done with the higher ratio benefit risks. The choice of the block will be done by an anesthesiologist expert in regional anaesthesia techniques. local anesthetic will be ropivacaine 0.5% posology according to the type of block
Study: NCT01965574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Study: NCT03915093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational nursing protocol
Description: It is a booklet given to study group ,which contains Knowledge and practice about thoracoscopy, pre - post operative care and home care instructions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine hospital care
Description: The routine care given by physicians and nurses after thoracoscopic surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine hospital care
Description: The routine care given by physicians and nurses after thoracoscopic surgery
Study: NCT02156934

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: paraurethral injection
Description: Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
Study: NCT03001817

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: K-877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for K-877)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for K-877)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Fenofibrate)
Study: NCT02835079

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen
Study: NCT03339843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Subjects will receive 200 mg of abemaciclib orally, two times a day, during cycles of 28 days each. An early FDG-PET/CT will be performed at cycle 1 day 14 to search for any new lesions.
Study: NCT02131649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FCH PET/MRI Scan
Description: Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
Study: NCT02921841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D*STAR

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: D*HEALTH
Description: Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
Study: NCT03501108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STOPPFrail deprescribing criteria
Description: STOPPFrail is a recently validated set of explicit deprescribing criteria devised specifically for use in older patients with advanced physical and /or mental morbidity such that the 1-year survival prognosis is likely to be poor. STOPPFrail-defined medications that appear on the patient's medication list are highlighted to the attending physician for his/her consideration for deprescribing i.e. removal from the medication list immediately or gradually as appropriate.
Study: NCT03210337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Topical Solution
Description: A-101 Topical Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle Solution
Description: A-101 Vehicle Solution
Study: NCT04565704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biopsy imaged by Optical imaging device.
Study: NCT00785382

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactulose Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Description: 150 mg Q12H x 2 doses
Study: NCT02637037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)
Description: single fixed-combination dose tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)
Description: single fixed-combination dose tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)
Description: single fixed-dose combination tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)
Description: single fixed-dose combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
Description: single fixed-dose combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)
Description: single fixed-dose combination tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Description: single fixed-dose combination tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Description: single fixed-dose combination tablets
Study: NCT00518089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin 0.5% eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo eye drops
Description: Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
Study: NCT04309097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention
Description: REAP is a live-streaming platform that allows users to shoot short videos or photos related to their physical exercise or eye relaxation (e.g., staring out of the window) using their smartphones. The app has been optimised to be used with the iPhone or Android.~When taking a online course recess, students will have access to the REAP platform that allows them to watch stay-at-home workout videos developed by exercise physiologists. Students will then be asked to create their own workout videos/photos and upload them to the live-streaming platform. When upload is completed, students will receive instant motivational messages to increase their engagement with the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information-only intervention
Description: Participants will have access to online health information and stay-at-home workout videos.
Study: NCT02164708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice.
Study: NCT02689362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: 1 tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: 1 tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin
Description: 1 tablet per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 1 tablet per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Evogliptin
Description: 1 tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Sitagliptin
Description: 1 tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Sitagliptin
Description: 1 tablet per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Sitagliptin
Description: 1 tablet per day
Study: NCT01048034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoetin
Description: For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
Study: NCT01733680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amiloride
Description: Subjects will take either amiloride hydrochloride or placebo for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral
Description: Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral
Description: Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
Study: NCT00476229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 1.5 mg/kg by vein on Days -11 to -7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Lymphoid Irradiation
Description: 80 cGy daily on days -11 to -7 and -4 to 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Infusion
Description: PBSC infusion administered on day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein on days -13, -6, 1, \& 8. Only those patients whose tumors express CD20 will receive Rituximab.
Study: NCT02578303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vascular flow measurement by PC-MRI
Description: participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels

Intervention type: OTHER
Group type: OTHER
Intervention: Vascular flow measurement by PC-MRI
Description: participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
Study: NCT03399929

Intervention type: OTHER
Intervention: Post Acute Rehabiltation

Intervention type: OTHER
Intervention: Post Acute Rehabiltation
Study: NCT01348516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KM-023
Description: -KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for KM-023
Description: -Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
Study: NCT02100696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrozulimab
Description: Participants will receive 105 mg etrolizumab administered by SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrozulimab
Description: Participants will receive 105 mg etrolizumab administered by SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrozulimab
Description: Participants will receive 105 mg etrolizumab administered by SC injection Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo (matched with etrolizumab) administered by SC injection Q4W.